| Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
|---|
| Brompheniramine | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | | | Brompheniramine | hsa00630 | Glyoxylate and dicarboxylate metabolism | 4.29E-03 | 2 | P40925, P15104 | MDH1, GLUL | More | | | Brompheniramine | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | | | Brompheniramine | hsa00983 | Drug metabolism - other enzymes | 3.50E-02 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | | | Brompheniramine | hsa01100 | Metabolic pathways | 4.11E-02 | 7 | P30041, P20839, P08237, Q86XP1, Q9UHK6, Q86VZ5, Q9NVH6 | PRDX6, IMPDH1, PFKM, DGKH, AMACR, SGMS1, TMLHE | More | | | Brompheniramine | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | | | Brompheniramine | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | | Brompheniramine | hsa03040 | Spliceosome | 6.28E-03 | 6 | Q14562, O43143, O60508, Q07955, Q01130, Q13243 | DHX8, DHX15, CDC40, SFRS1, SFRS2, SFRS5 | More | | | Brompheniramine | hsa03050 | Proteasome | 1.21E-02 | 1 | P28074 | PSMB5 | More | | | Brompheniramine | hsa03320 | PPAR signaling pathway | 4.33E-02 | 2 | Q6PCB7, Q9UNU6 | SLC27A1, CYP8B1 | More | | | Brompheniramine | hsa04024 | cAMP signaling pathway | 4.38E-02 | 4 | P42338, P0DP23, Q13370, Q13009 | PIK3CB, CALM1, PDE3B, TIAM1 | More | | | Brompheniramine | hsa04064 | NF-kappa B signaling pathway | 1.60E-02 | 8 | P10415, O00463, Q04759, Q9UDY8, Q16548, Q13315, P24522, P09341 | BCL2, TRAF5, PRKCQ, MALT1, BCL2A1, ATM, GADD45A, CXCL1 | More | | | Brompheniramine | hsa04070 | Phosphatidylinositol signaling system | 4.86E-02 | 3 | P0DP23, P42338, P27987 | CALM1, PIK3CB, ITPKB | More | | | Brompheniramine | hsa04071 | Sphingolipid signaling pathway | 2.96E-02 | 5 | P21453, Q9H228, Q13362, Q9BX95, P10415 | S1PR1, EDG8, PPP2R5C, SGPP1, BCL2 | More | | | Brompheniramine | hsa04080 | Neuroactive ligand-receptor interaction | 3.22E-02 | 7 | P08311, Q15722, P21453, Q9H228, O00398, P21730, Q16581 | CTSG, LTB4R, S1PR1, EDG8, P2RY10, C5AR1, C3AR1 | More | | | Brompheniramine | hsa04114 | Oocyte meiosis | 6.23E-03 | 5 | Q9Y6D9, P51812, Q02750, P16298, Q17RY0 | MAD1L1, RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | | | Brompheniramine | hsa04115 | p53 signaling pathway | 3.98E-02 | 5 | P24522, Q13315, Q53FA7, O95067, P10415 | GADD45A, ATM, TP53I3, CCNB2, BCL2 | More | | | Brompheniramine | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | | Brompheniramine | hsa04210 | Apoptosis | 3.77E-02 | 8 | Q13315, P10415, O76075, P24522, Q16548, P43234, P18848, Q14643 | ATM, BCL2, DFFB, GADD45A, BCL2A1, CTSO, ATF4, ITPR1 | More | | | Brompheniramine | hsa04217 | Necroptosis | 2.34E-02 | 4 | P01375, P48023, Q14765, Q99878 | TNF, FASLG, STAT4, H2AC14 | More | | | Brompheniramine | hsa04330 | Notch signaling pathway | 7.49E-03 | 2 | Q92542, P49768 | NCSTN, PSEN1 | More | | | Brompheniramine | hsa04360 | Axon guidance | 1.71E-02 | 4 | P20827, O95631, P42338, P23528 | EFNA1, NTN1, PIK3CB, CFL1 | More | | | Brompheniramine | hsa04370 | VEGF signaling pathway | 3.06E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | | | Brompheniramine | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 4.73E-02 | 3 | Q13873, Q02750, Q86SE9 | BMPR2, MAP2K1, PCGF5 | More | | | Brompheniramine | hsa04612 | Antigen processing and presentation | 3.21E-02 | 6 | P13765, P48382, P26715, P26717, Q13241, P01732 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, CD8A | More | | | Brompheniramine | hsa04613 | Neutrophil extracellular trap formation | 4.20E-02 | 5 | P04908, Q93077, P68431, O43315, Q16539 | H2AC4; H2AC8, HIST1H2AC, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, AQP9, MAPK14 | More | | | Brompheniramine | hsa04650 | Natural killer cell mediated cytotoxicity | 3.73E-02 | 3 | P16298, P50591, Q02750 | PPP3CB, TNFSF10, MAP2K1 | More | | | Brompheniramine | hsa04659 | Th17 cell differentiation | 4.38E-02 | 4 | P42224, P14784, P40189, P08238 | STAT1, IL2RB, IL6ST, HSP90AB1 | More | | | Brompheniramine | hsa04666 | Fc gamma R-mediated phagocytosis | 3.08E-02 | 3 | P42338, P23528, P14598 | PIK3CB, CFL1, NCF1 | More | | | Brompheniramine | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | | Brompheniramine | hsa04720 | Long-term potentiation | 2.85E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | | | Brompheniramine | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | | Brompheniramine | hsa04725 | Cholinergic synapse | 4.83E-02 | 4 | P22694, Q14643, P18848, P10415 | PRKACB, ITPR1, ATF4, BCL2 | More | | | Brompheniramine | hsa04914 | Progesterone-mediated oocyte maturation | 9.70E-04 | 7 | Q17RY0, P42338, Q13370, Q9Y6D9, P08238, P51812, Q02750 | CPEB4, PIK3CB, PDE3B, MAD1L1, HSP90AB1, RPS6KA3, MAP2K1 | More | | | Brompheniramine | hsa04915 | Estrogen signaling pathway | 2.96E-02 | 5 | P14780, P22694, P18848, Q14643, P10415 | MMP9, PRKACB, ATF4, ITPR1, BCL2 | More | | | Brompheniramine | hsa04918 | Thyroid hormone synthesis | 3.50E-02 | 3 | P22694, P18848, Q14643 | PRKACB, ATF4, ITPR1 | More | | | Brompheniramine | hsa04919 | Thyroid hormone signaling pathway | 3.71E-02 | 2 | P26678, P08237 | PLN, PFKM | More | | | Brompheniramine | hsa04924 | Renin secretion | 3.77E-02 | 2 | Q13370, P0DP23 | PDE3B, CALM1 | More | | | Brompheniramine | hsa04927 | Cortisol synthesis and secretion | 8.60E-03 | 3 | Q14643, P18848, P22694 | ITPR1, ATF4, PRKACB | More | | | Brompheniramine | hsa04928 | Parathyroid hormone synthesis, secretion and action | 2.13E-02 | 5 | Q14643, P22694, P23771, P18848, P10415 | ITPR1, PRKACB, GATA3, ATF4, BCL2 | More | | | Brompheniramine | hsa04932 | Non-alcoholic fatty liver disease | 2.44E-03 | 5 | P01375, P49841, P48023, Q16718, O14521 | TNF, GSK3B, FASLG, NDUFA5, SDHD | More | | | Brompheniramine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | | Brompheniramine | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | | | Brompheniramine | hsa05017 | Spinocerebellar ataxia | 2.43E-02 | 1 | P28074 | PSMB5 | More | | | Brompheniramine | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | | | Brompheniramine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | | | Brompheniramine | hsa05100 | Bacterial invasion of epithelial cells | 2.85E-02 | 3 | Q14141, Q05397, Q96JJ3 | SEPT6, PTK2, ELMO2 | More | | | Brompheniramine | hsa05135 | Yersinia infection | 3.29E-02 | 4 | Q05397, P51812, Q02750, Q96JJ3 | PTK2, RPS6KA3, MAP2K1, ELMO2 | More | | | Brompheniramine | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | | | Brompheniramine | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | | Brompheniramine | hsa05168 | Herpes simplex virus 1 infection | 1.15E-02 | 8 | P42224, Q07955, Q01130, Q13243, P42338, Q13398, Q03923, Q9UDV6 | STAT1, SFRS1, SFRS2, SFRS5, PIK3CB, ZNF211, ZNF85, ZNF212 | More | | | Brompheniramine | hsa05200 | Pathways in cancer | 3.92E-02 | 9 | P42338, P08238, P42224, P43246, P14923, O75293, P0DP23, P14784, P40189 | PIK3CB, HSP90AB1, STAT1, MSH2, JUP, GADD45B, CALM1, IL2RB, IL6ST | More | | | Brompheniramine | hsa05202 | Transcriptional misregulation in cancer | 1.77E-02 | 11 | Q15532, Q13315, P14780, Q15744, Q16548, O15550, P05164, P12838, P08246, Q9C0K0, P24522 | SS18, ATM, MMP9, CEBPE, BCL2A1, UTX, MPO, DEFA4, ELA2, BCL11B, GADD45A | More | | | Brompheniramine | hsa05212 | Pancreatic cancer | 1.72E-02 | 3 | P42338, P42224, O75293 | PIK3CB, STAT1, GADD45B | More | | | Brompheniramine | hsa05214 | Glioma | 1.72E-02 | 3 | P0DP23, P42338, O75293 | CALM1, PIK3CB, GADD45B | More | | | Brompheniramine | hsa05321 | Inflammatory bowel disease | 2.29E-02 | 4 | P13765, Q14765, P23771, Q9HBE5 | HLA-DOB, STAT4, GATA3, IL21R | More | | | Brompheniramine | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | | Brompheniramine | hsa05332 | Graft-versus-host disease | 7.94E-04 | 6 | P13765, P48023, P10747, P01375, P26715, Q13241 | HLA-DOB, FASLG, CD28, TNF, KLRC1, KLRD1 | More | | | Brompheniramine | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | | | Brompheniramine | hsa05418 | Fluid shear stress and atherosclerosis | 3.73E-02 | 4 | P42338, P14598, P0DP23, P08238 | PIK3CB, NCF1, CALM1, HSP90AB1 | More | | | Dexbrompheniramine | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | | | Dexbrompheniramine | hsa00630 | Glyoxylate and dicarboxylate metabolism | 4.29E-03 | 2 | P40925, P15104 | MDH1, GLUL | More | | | Dexbrompheniramine | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | | | Dexbrompheniramine | hsa00983 | Drug metabolism - other enzymes | 3.50E-02 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | | | Dexbrompheniramine | hsa01100 | Metabolic pathways | 4.11E-02 | 7 | P30041, P20839, P08237, Q86XP1, Q9UHK6, Q86VZ5, Q9NVH6 | PRDX6, IMPDH1, PFKM, DGKH, AMACR, SGMS1, TMLHE | More | | | Dexbrompheniramine | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | | | Dexbrompheniramine | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | | Dexbrompheniramine | hsa03040 | Spliceosome | 6.28E-03 | 6 | Q14562, O43143, O60508, Q07955, Q01130, Q13243 | DHX8, DHX15, CDC40, SFRS1, SFRS2, SFRS5 | More | | | Dexbrompheniramine | hsa03050 | Proteasome | 1.21E-02 | 1 | P28074 | PSMB5 | More | | | Dexbrompheniramine | hsa03320 | PPAR signaling pathway | 4.33E-02 | 2 | Q6PCB7, Q9UNU6 | SLC27A1, CYP8B1 | More | | | Dexbrompheniramine | hsa04024 | cAMP signaling pathway | 4.38E-02 | 4 | P42338, P0DP23, Q13370, Q13009 | PIK3CB, CALM1, PDE3B, TIAM1 | More | | | Dexbrompheniramine | hsa04064 | NF-kappa B signaling pathway | 1.60E-02 | 8 | P10415, O00463, Q04759, Q9UDY8, Q16548, Q13315, P24522, P09341 | BCL2, TRAF5, PRKCQ, MALT1, BCL2A1, ATM, GADD45A, CXCL1 | More | | | Dexbrompheniramine | hsa04070 | Phosphatidylinositol signaling system | 4.86E-02 | 3 | P0DP23, P42338, P27987 | CALM1, PIK3CB, ITPKB | More | | | Dexbrompheniramine | hsa04071 | Sphingolipid signaling pathway | 2.96E-02 | 5 | P21453, Q9H228, Q13362, Q9BX95, P10415 | S1PR1, EDG8, PPP2R5C, SGPP1, BCL2 | More | | | Dexbrompheniramine | hsa04080 | Neuroactive ligand-receptor interaction | 3.22E-02 | 7 | P08311, Q15722, P21453, Q9H228, O00398, P21730, Q16581 | CTSG, LTB4R, S1PR1, EDG8, P2RY10, C5AR1, C3AR1 | More | | | Dexbrompheniramine | hsa04114 | Oocyte meiosis | 6.23E-03 | 5 | Q9Y6D9, P51812, Q02750, P16298, Q17RY0 | MAD1L1, RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | | | Dexbrompheniramine | hsa04115 | p53 signaling pathway | 3.98E-02 | 5 | P24522, Q13315, Q53FA7, O95067, P10415 | GADD45A, ATM, TP53I3, CCNB2, BCL2 | More | | | Dexbrompheniramine | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | | Dexbrompheniramine | hsa04210 | Apoptosis | 3.77E-02 | 8 | Q13315, P10415, O76075, P24522, Q16548, P43234, P18848, Q14643 | ATM, BCL2, DFFB, GADD45A, BCL2A1, CTSO, ATF4, ITPR1 | More | | | Dexbrompheniramine | hsa04217 | Necroptosis | 2.34E-02 | 4 | P01375, P48023, Q14765, Q99878 | TNF, FASLG, STAT4, H2AC14 | More | | | Dexbrompheniramine | hsa04330 | Notch signaling pathway | 7.49E-03 | 2 | Q92542, P49768 | NCSTN, PSEN1 | More | | | Dexbrompheniramine | hsa04360 | Axon guidance | 1.71E-02 | 4 | P20827, O95631, P42338, P23528 | EFNA1, NTN1, PIK3CB, CFL1 | More | | | Dexbrompheniramine | hsa04370 | VEGF signaling pathway | 3.06E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | | | Dexbrompheniramine | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 4.73E-02 | 3 | Q13873, Q02750, Q86SE9 | BMPR2, MAP2K1, PCGF5 | More | | | Dexbrompheniramine | hsa04612 | Antigen processing and presentation | 3.21E-02 | 6 | P13765, P48382, P26715, P26717, Q13241, P01732 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, CD8A | More | | | Dexbrompheniramine | hsa04613 | Neutrophil extracellular trap formation | 4.20E-02 | 5 | P04908, Q93077, P68431, O43315, Q16539 | H2AC4; H2AC8, HIST1H2AC, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, AQP9, MAPK14 | More | | | Dexbrompheniramine | hsa04650 | Natural killer cell mediated cytotoxicity | 3.73E-02 | 3 | P16298, P50591, Q02750 | PPP3CB, TNFSF10, MAP2K1 | More | | | Dexbrompheniramine | hsa04659 | Th17 cell differentiation | 4.38E-02 | 4 | P42224, P14784, P40189, P08238 | STAT1, IL2RB, IL6ST, HSP90AB1 | More | | | Dexbrompheniramine | hsa04666 | Fc gamma R-mediated phagocytosis | 3.08E-02 | 3 | P42338, P23528, P14598 | PIK3CB, CFL1, NCF1 | More | | | Dexbrompheniramine | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | | Dexbrompheniramine | hsa04720 | Long-term potentiation | 2.85E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | | | Dexbrompheniramine | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | | Dexbrompheniramine | hsa04725 | Cholinergic synapse | 4.83E-02 | 4 | P22694, Q14643, P18848, P10415 | PRKACB, ITPR1, ATF4, BCL2 | More | | | Dexbrompheniramine | hsa04914 | Progesterone-mediated oocyte maturation | 9.70E-04 | 7 | Q17RY0, P42338, Q13370, Q9Y6D9, P08238, P51812, Q02750 | CPEB4, PIK3CB, PDE3B, MAD1L1, HSP90AB1, RPS6KA3, MAP2K1 | More | | | Dexbrompheniramine | hsa04915 | Estrogen signaling pathway | 2.96E-02 | 5 | P14780, P22694, P18848, Q14643, P10415 | MMP9, PRKACB, ATF4, ITPR1, BCL2 | More | | | Dexbrompheniramine | hsa04918 | Thyroid hormone synthesis | 3.50E-02 | 3 | P22694, P18848, Q14643 | PRKACB, ATF4, ITPR1 | More | | | Dexbrompheniramine | hsa04919 | Thyroid hormone signaling pathway | 3.71E-02 | 2 | P26678, P08237 | PLN, PFKM | More | | | Dexbrompheniramine | hsa04924 | Renin secretion | 3.77E-02 | 2 | Q13370, P0DP23 | PDE3B, CALM1 | More | | | Dexbrompheniramine | hsa04927 | Cortisol synthesis and secretion | 8.60E-03 | 3 | Q14643, P18848, P22694 | ITPR1, ATF4, PRKACB | More | | | Dexbrompheniramine | hsa04928 | Parathyroid hormone synthesis, secretion and action | 2.13E-02 | 5 | Q14643, P22694, P23771, P18848, P10415 | ITPR1, PRKACB, GATA3, ATF4, BCL2 | More | | | Dexbrompheniramine | hsa04932 | Non-alcoholic fatty liver disease | 2.44E-03 | 5 | P01375, P49841, P48023, Q16718, O14521 | TNF, GSK3B, FASLG, NDUFA5, SDHD | More | | | Dexbrompheniramine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | | Dexbrompheniramine | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | | | Dexbrompheniramine | hsa05017 | Spinocerebellar ataxia | 2.43E-02 | 1 | P28074 | PSMB5 | More | | | Dexbrompheniramine | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | | | Dexbrompheniramine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | | | Dexbrompheniramine | hsa05100 | Bacterial invasion of epithelial cells | 2.85E-02 | 3 | Q14141, Q05397, Q96JJ3 | SEPT6, PTK2, ELMO2 | More | | | Dexbrompheniramine | hsa05135 | Yersinia infection | 3.29E-02 | 4 | Q05397, P51812, Q02750, Q96JJ3 | PTK2, RPS6KA3, MAP2K1, ELMO2 | More | | | Dexbrompheniramine | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | | | Dexbrompheniramine | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | | Dexbrompheniramine | hsa05168 | Herpes simplex virus 1 infection | 1.15E-02 | 8 | P42224, Q07955, Q01130, Q13243, P42338, Q13398, Q03923, Q9UDV6 | STAT1, SFRS1, SFRS2, SFRS5, PIK3CB, ZNF211, ZNF85, ZNF212 | More | | | Dexbrompheniramine | hsa05200 | Pathways in cancer | 3.92E-02 | 9 | P42338, P08238, P42224, P43246, P14923, O75293, P0DP23, P14784, P40189 | PIK3CB, HSP90AB1, STAT1, MSH2, JUP, GADD45B, CALM1, IL2RB, IL6ST | More | | | Dexbrompheniramine | hsa05202 | Transcriptional misregulation in cancer | 1.77E-02 | 11 | Q15532, Q13315, P14780, Q15744, Q16548, O15550, P05164, P12838, P08246, Q9C0K0, P24522 | SS18, ATM, MMP9, CEBPE, BCL2A1, UTX, MPO, DEFA4, ELA2, BCL11B, GADD45A | More | | | Dexbrompheniramine | hsa05212 | Pancreatic cancer | 1.72E-02 | 3 | P42338, P42224, O75293 | PIK3CB, STAT1, GADD45B | More | | | Dexbrompheniramine | hsa05214 | Glioma | 1.72E-02 | 3 | P0DP23, P42338, O75293 | CALM1, PIK3CB, GADD45B | More | | | Dexbrompheniramine | hsa05321 | Inflammatory bowel disease | 2.29E-02 | 4 | P13765, Q14765, P23771, Q9HBE5 | HLA-DOB, STAT4, GATA3, IL21R | More | | | Dexbrompheniramine | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | | Dexbrompheniramine | hsa05332 | Graft-versus-host disease | 7.94E-04 | 6 | P13765, P48023, P10747, P01375, P26715, Q13241 | HLA-DOB, FASLG, CD28, TNF, KLRC1, KLRD1 | More | | | Dexbrompheniramine | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | | | Dexbrompheniramine | hsa05418 | Fluid shear stress and atherosclerosis | 3.73E-02 | 4 | P42338, P14598, P0DP23, P08238 | PIK3CB, NCF1, CALM1, HSP90AB1 | More | |
|
